News
Browse all news articles and resources.
Featured
3 articles
Esketamine vs. Troches: What TRD Patients Should Know
A new clinical review on esketamine for TRD highlights access barriers and patient preferences — here's what it means for ketamine troche therapy.
Esketamine TRD Access Gaps Open Doors for Troches
New clinician data on esketamine for TRD reveals access barriers that make compounded ketamine troches a practical frontline option for many patients.
France Approves IV Ketamine for Suicidal Crisis: What It Means
France has approved IV ketamine for acute suicidal crises. Here's what this global shift means for ketamine troche patients and at-home treatment access in the U.S.
Esketamine vs. Troches: What TRD Patients Should Know
A new clinical review on esketamine for TRD highlights access barriers and patient preferences — here's what it means for ketamine troche therapy.
Esketamine TRD Access Gaps Open Doors for Troches
New clinician data on esketamine for TRD reveals access barriers that make compounded ketamine troches a practical frontline option for many patients.
France Approves IV Ketamine for Suicidal Crisis: What It Means
France has approved IV ketamine for acute suicidal crises. Here's what this global shift means for ketamine troche patients and at-home treatment access in the U.S.
Glutamate Pathways Are Reshaping TRD Treatment
A 2026 review highlights how glutamate-targeting drugs like esketamine and ketamine troches are redefining treatment-resistant depression care.
Glutamate Pathway Treatments Reshape TRD Care
New research highlights glutamate-based treatments for treatment-resistant depression. Here's what it means for ketamine troche patients in 2026.
BXCL501 Enters Phase 2a for Acute Stress and PTSD Prevention
BioXcel's sublingual dexmedetomidine enters a DoD-backed Phase 2a trial for acute stress reactions — what it means for the trauma treatment landscape.
BXCL501 PTSD Trial: What It Means for Ketamine Users
A new DoD-backed BXCL501 trial targets acute stress reactions and PTSD prevention. Here's what ketamine troche patients should know.
Glutamate Pathway Treatments Reshape TRD Care in 2026
New research highlights glutamate-targeting treatments for TRD, including esketamine and ketamine troches. Here's what it means for your care plan.